VRC-CHKVLP059-00-VP

Bharat Biotech's oral cholera vaccine Hillchol has demonstrated non-inferiority against both Ogawa and Inaba serotypes in Phase III clinical trials involving 1,800 participants across India.

TriLink BioTechnologies and the International Vaccine Institute (IVI) have signed a Memorandum of Understanding to collaborate on mRNA-based vaccine development and promote equitable access in low- and middle-income countries.

FDA Commissioner Martin Makary announced an agency-wide rollout of AI tools to assist with scientific reviews across all 11 FDA centers, with full deployment expected by June 30, 2025.

European Medicines Agency has suspended the use of Valneva's IXCHIQ chikungunya vaccine in people over 65 years old following reports of 17 serious adverse events, including two deaths, in elderly patients.

Inventiva announces strategic pipeline prioritization, halting all preclinical research to focus exclusively on lanifibranor development for MASH treatment, with planned 50% workforce reduction.